Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced that the District Court for the Southern District of New York has issued a decision in the patent litigation brought against Momenta by Teva in August of 2008. The court found all the claims infringed and not invalid or unenforceable. The decision is subject to appeal.

"We are disappointed that the court determined that Teva's patents were valid and infringed, and we look forward to reading the full opinion to understand its reasoning," commented Craig Wheeler, President and Chief Executive Officer of Momenta. "We remain confident in our legal position and we intend to appeal."

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.